Blueprint Medicines Co. (NASDAQ:BPMC) Receives $120.00 Consensus Target Price from Analysts

Blueprint Medicines Co. (NASDAQ:BPMC) has been given a consensus rating of “Moderate Buy” by the twenty analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $118.22.

BPMC has been the topic of several research reports. Morgan Stanley increased their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Oppenheimer raised their price target on Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, July 8th. Barclays upped their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, July 29th. Needham & Company LLC reiterated a “buy” rating and issued a $130.00 target price on shares of Blueprint Medicines in a research note on Thursday, August 1st. Finally, Robert W. Baird boosted their price target on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd.

Insider Buying and Selling at Blueprint Medicines

In related news, insider Philina Lee sold 41,913 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

A number of institutional investors and hedge funds have recently modified their holdings of the company. Triad Wealth Partners LLC acquired a new stake in Blueprint Medicines during the second quarter valued at approximately $27,000. Covestor Ltd grew its holdings in shares of Blueprint Medicines by 9,700.0% in the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 291 shares during the period. Headlands Technologies LLC increased its holdings in shares of Blueprint Medicines by 105.2% in the first quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 342 shares in the last quarter. Natixis bought a new stake in Blueprint Medicines during the 1st quarter worth approximately $73,000. Finally, CWM LLC increased its position in shares of Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares in the last quarter.

Blueprint Medicines Trading Down 1.6 %

Shares of BPMC opened at $83.09 on Tuesday. The stock has a market cap of $5.20 billion, a PE ratio of -17.27 and a beta of 0.58. Blueprint Medicines has a 12 month low of $43.89 and a 12 month high of $121.90. The stock’s 50-day moving average is $89.77 and its two-hundred day moving average is $98.55. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company had revenue of $138.20 million during the quarter, compared to analyst estimates of $104.02 million. During the same period last year, the business earned ($2.19) EPS. The firm’s revenue for the quarter was up 139.9% compared to the same quarter last year. Equities analysts forecast that Blueprint Medicines will post -3.99 earnings per share for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.